Onconova Therapeutics Inc Share Price Nasdaq
Equities
US68232V3069
Biotechnology & Medical Research
Sales 2024 * | 210K 16.39M | Sales 2025 * | 300K 23.41M | Capitalization | 12.61M 984M |
---|---|---|---|---|---|
Net income 2024 * | -23M -1.79B | Net income 2025 * | -28M -2.18B | EV / Sales 2024 * | 60 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 42 x |
P/E ratio 2024 * |
-0.69
x | P/E ratio 2025 * |
-0.72
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.39% |
Latest transcript on Onconova Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Steven Fruchtman
PSD | President | 73 | 18/01/15 |
Mark Guerin
DFI | Director of Finance/CFO | 55 | 31/08/13 |
Meena Arora
CTO | Chief Tech/Sci/R&D Officer | - | 23/10/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Marino
BRD | Director/Board Member | 74 | 30/06/15 |
Jack Stover
BRD | Director/Board Member | 69 | 22/05/16 |
Mary Shoemaker
BRD | Director/Board Member | 63 | 31/03/20 |
1st Jan change | Capi. | |
---|---|---|
+48.64% | 54.63B | |
-6.44% | 39.92B | |
+37.07% | 38.82B | |
+14.28% | 26.86B | |
-11.17% | 26.22B | |
-21.40% | 18.78B | |
+25.64% | 12.21B | |
+0.96% | 12.16B | |
+27.04% | 11.94B |